Selection of cholesterol absorption inhibitors devoid of secondary intestinal effects.
The digestive tolerance of cholesterol absorption inhibitors, which requires a constant improvement, was the main purpose of this study. Given the known hypocholesterolemic and antiatherosclerotic properties of some steroid glycosides, we synthesized a series of sterol derivatives by coupling some phytosterols known to interact with sterol absorption and also to be poorly absorbed to a cationic group. The first derivative was a potent inhibitor of cholesterol absorption and a potent hypocholesterolemic agent in different animal models, but was responsible for severe gastro-intestinal side-effects. In order to control the tolerance of the newly synthesized compounds, cholesterol and taurocholate absorption were measured in the jejunum and in the ileum, respectively. The intestinal water and ionic transport and the estimation of histological changes in the intestinal mucosae were determined simultaneously. The in-situ isolated loop technique, in anaesthetized rats, allowed the simultaneous control of these three parameters which were used to select the best derivative, inhibitor of cholesterol absorption devoid of any deleterious effect, as seen via a three-dimensional representation. The results showed that it was possible to obtain a specific cholesterol absorption inhibitor without secretory and deleterious effects and suggested that the amphiphilic characteristics of the molecules were responsible for their deleterious effects on digestive tract.
Marquet
F
F
Inserm U 45, Hôpital E-Herriot, Lyon, France.
Abou el Fadil
F
F
Boubia
B
B
Guffroy
C
C
Pansu
D
D
Descroix-Vagne
M
M
D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002250:Carbon Radioisotopes; D000077286:Cetrimonium; D002593:Cetrimonium Compounds / Q000008:administration & dosage / Q000494:pharmacology; D002784:Cholesterol / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D002792:Cholestyramine Resin / Q000008:administration & dosage / Q000494:pharmacology; D015331:Cohort Studies; D004072:Digitonin / Q000008:administration & dosage / Q000494:pharmacology; D004144:Diosgenin / Q000008:administration & dosage / Q000494:pharmacology; D004333:Drug Administration Routes; D007408:Intestinal Absorption / Q000187:drug effects* / Q000502:physiology; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D012503:Saponins / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D013656:Taurocholic Acid / Q000008:administration & dosage / Q000494:pharmacology; D014316:Tritium
D000924:Anticholesteremic Agents; D002250:Carbon Radioisotopes; D002593:Cetrimonium Compounds; D012503:Saponins; D014316:Tritium; D002792:Cholestyramine Resin; C080606:tiqueside; D013656:Taurocholic Acid; D002784:Cholesterol; D004144:Diosgenin; D004072:Digitonin; D000077286:Cetrimonium